- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Rennee Rayburg, RPh, Discusses the Top Down Approach in Specialty Drug Management
Renee Rayburg, RPh, Manager Clinical Pharmacy, OptumInsight, states that if providers narrowly focus on the traditional top down approach in specialty drug management they may miss out on opportunities for additional cost savings.
Renee Rayburg, RPh, Manager Clinical Pharmacy, OptumInsight, states that if providers narrowly focus on the traditional top down approach in specialty drug management they may miss out on opportunities for additional cost savings.
When providers only focus on their top drivers, they fail to recognize the impact specialty drug patients can have on pushing higher costs. Rayburg says, “When you look at a rare disease and a drug that might cost you a couple hundred thousand dollars a year, it’s going to make a difference if you have one or two of those in your population of people.”
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More
